New Mexico Register / Volume XXXI, Issue
6 / March 24, 2020
This is
an amendment to 16.10.14 NMAC, Section 7 and add a new Section 13, effective 3/24/2020.
Statute citations were changed throughout the rule to
conform to correct legislative style.
16.10.14.7 DEFINITIONS:
A. “Acute
pain” means the normal, predicted physiological response to a noxious
chemical or thermal or mechanical stimulus, typically associated with invasive
procedures, trauma or disease and is generally time-limited.
B. “Addiction”
is a neurobehavioral syndrome with genetic and environmental influences that
results in psychological dependence on the use of substances for their psychic
effects. It is characterized by
behaviors that include one or more of the following: impaired control over drug
use; compulsive use; continued use despite harm; and, craving. Physical dependence and tolerance are normal
physiological consequences of extended opioid therapy for pain and should not
by themselves be considered addiction.
C. “Benzodiazepine” means any controlled substance referenced at
Subsection A of 16.19.20.68 NMAC, as
may be amended from time to time.
D. “Chronic
pain” means pain that persists after reasonable medical efforts have been
made to relieve the pain or its cause and that continues, either continuously
or episodically, for longer than three consecutive months. “Chronic pain” does not, for purpose of the
Pain Relief Act requirements, include pain associated with a terminal condition
or with a progressive disease that, in the normal course of progression, may
reasonably be expected to result in a terminal condition.
E. “Clinical
expert” means a person who, by reason of specialized education or
substantial relevant experience in pain management, has knowledge regarding current
standards, practices and guidelines.
F. “Controlled
Substance” means a drug or substance listed in schedules I through V of the
Controlled Substances Act or regulations adopted thereto.
G. “Delegate” means a person
designated by a practitioner pursuant to 16.19.29.9 NMAC for the purpose of
requesting and receiving prescription monitoring program (PMP) reports for that
practitioner.
H. “Opioid” means the class of
drugs that includes the natural derivatives of opium, which are morphine and
codeine, and related synthetic and semi-synthetic compounds that act upon
opioid receptors.
I. “Opioid
antagonist” means a drug approved by the federal food and drug
administration that when administered negates or neutralizes in whole or in
part the pharmacological effects of an opioid analgesic in the body, including
naloxone and such other medications approved by the board of pharmacy for the
reversal of opioid analgesic overdoses.
[K.]
J. “Pain” means acute or
chronic pain or both.
[L.] K. “Physical dependence”
means a state of adaptation that is manifested by a drug-specific withdrawal
syndrome that can be produced by abrupt cessation, rapid dose reduction,
decreasing blood level of the drug, administration of an antagonist, or a
combination of these.
[M.] L. “Practitioner” means a New Mexico
medical board licensee maintaining licensure pursuant to state law that allows
that individual to prescribe, order, administer or dispense controlled
substances to patients (see 16.19.29.7 NMAC).
[N.]
M. “Prescription monitoring
program” means a centralized system to collect, monitor, and analyze
electronically, for controlled substances, prescribing and dispensing data
submitted by pharmacies and dispensing practitioners. The data are used to support efforts in
education, research, enforcement and abuse prevention.
[O.]
N. “Schedule II-V” refers
to any controlled substance listed in schedule II, III, IV, or V of the
Controlled Substances Act found at Chapter 30, Article 31 NMSA 1978,
regulations promulgated by the New Mexico board of pharmacy found at 16.19.20
NMAC, or federal controlled substances regulations promulgated pursuant to 21
U.S.C. 812.
[P.]
O. “Stimulant” means any controlled substance referenced in
Subsection C of 16.19.20.66 NMAC, Subsection A of 16.19.20.67 NMAC, Subsection
D of 16.19.20.68 NMAC, or Subsection B of 16.19.20.69 NMAC, as may be amended
from time to time.
[Q.]
P. “Therapeutic purpose”
means the use of pharmaceutical and non-pharmaceutical medical treatment that
conforms substantially to accepted guidelines for pain management and other
conditions.
[R.]
Q “Tolerance” means a
state of adaptation in which exposure to a drug induces changes that result in
a diminution of one or more of the drug’s effects over time.
[16.10.14.7 NMAC - N,
1/20/2003; A, 9/28/2012; A, 11/30/2016; A, 3/24/2020]
16.10.14.13 REQUIREMENTS FOR LICENSEES OF THE NEW MEXICO MEDICAL
BOARD WHO PRESCRIBE, DISTRIBUTE OR DISPENSE OPIOID ANALGESICS.
A. A health
care provider who prescribes, distributes or dispenses
an opioid analgesic for the first time to a patient shall advise the patient on
the risks of overdose and inform the patient of the availability of an opioid
antagonist. With respect to a patient to
whom an opioid analgesic has previously been prescribed, distributed or
dispensed by the health care provider, the health care provider shall advise
the patient on the risks of overdose and inform the patient of the availability
of an opioid antagonist on the first occasion that the health care provider
prescribes, distributes or dispenses an opioid analgesic each calendar year.
B. A
health care provider who prescribes an opioid analgesic for a patient shall
co-prescribe an opioid antagonist if the amount of opioid analgesic being prescribed
is at least a five-day supply. The
prescription for the opioid antagonist shall be accompanied by written
information regarding the temporary effects of the opioid antagonist and
techniques for administering the opioid antagonist. That written information shall contain a
warning that a person administering the opioid antagonist should call
911immediately after administering the opioid antagonist.
[16.10.14.13 NMAC - N,
3/24/2020]